Harbor Health Care ETF (MEDI)
- Previous Close
25.42 - Open
26.03 - Bid 12.66 x 1000
- Ask --
- Day's Range
25.25 - 25.32 - 52 Week Range
20.91 - 27.48 - Volume
4,310 - Avg. Volume
6,604 - Net Assets 10.18M
- NAV 25.28
- PE Ratio (TTM) 38.54
- Yield 0.60%
- YTD Daily Total Return 1.88%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.80%
The fund invests primarily in equity securities, principally common and preferred stocks of companies of any market capitalization. Under normal market conditions, the fund invests at least 80% of its net assets, plus borrowings for investment purposes, in securities of companies principally engaged in the research, development, production, or distribution of products and services related to the health care industry (“health care companies”). It is non-diversified.
Harbor
Fund Family
Health
Fund Category
10.18M
Net Assets
2022-11-16
Inception Date
Performance Overview: MEDI
Trailing returns as of 4/25/2024. Category is Health.
People Also Watch
Holdings: MEDI
Top 10 Holdings (63.22% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: MEDI
Analyst Report: Incyte Corp.
Founded in 1991 and based in Wilmington, Delaware, Incyte is a drug discovery and development company. The company has several small-molecule compounds in clinical trials, while its primary revenue-generating products include Jakafi, Opzelura, Iclusig, Pemazyre, and Olumiant. Jakafi treats polycythemia vera (PV), a type of blood cancer; myelofibrosis (MF), a rare bone marrow disorder; and steroid-refractory acute graft-versus-host-disease (GVHD), while Opzelura treats eczema and vitiligo, Iclusig treats leukemia, Pemazyre treats bile duct cancer, and Olumiant treats rheumatoid arthritis. The company also recently launched Tabrecta, for non-small-cell lung cancer, and has several active Phase 2 and 3 programs in oncology.
RatingPrice TargetMarket Digest: FCX, FI, INCY, PG, STX, T, OC
Despite April Stumble, Positive Stock-Market Outlook for 2024
MYGN: Lowering target price to $20.00
MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetMYGN: Raising target price to $22.00
MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $22.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target